MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 177
- Registration Number
- NCT01251146
- Locations
- 🇨🇳
Beijing Shi Jingshan Hospital, Beijing, China
🇨🇳Shanghai Institute of Hypertension, Shanghai, China
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 553
- Registration Number
- NCT01228734
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳The Affiliated Hospital of Medical College Qingdao University, Qingdao, Shandong, China
🇨🇳Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
EXpression PRofile Endometrium Samples Study
- First Posted Date
- 2010-09-28
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 27
- Registration Number
- NCT01210144
- Locations
- 🇫🇷
Research Site, Paris, France
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
Phase 4
Completed
- Conditions
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 79
- Registration Number
- NCT01201343
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 129
- Registration Number
- NCT01198132
- Locations
- 🇫🇷
CHU Hôpital Gui de Chauliac Service de Neurologie B, Montpellier, France
Observational Study With Prospective and/or Retrospective Follow-up, Without Modifying Patient Treatment and Follow-up Practices for the Initial Treatment of Hypothyroidism in France
Completed
- Conditions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1285
- Registration Number
- NCT01197183
- Locations
- 🇫🇷
Merck Lipha Santé Laboratories, Saint Romain, Lyon, France
A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation
Completed
- Conditions
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 356
- Registration Number
- NCT01196143
- Locations
- 🇬🇷
Centre of Assisted Reproduction "Embryoland", Athens, Greece
Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone
Completed
- Conditions
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 443
- Registration Number
- NCT01196156
- Locations
- 🇪🇸
Hospital Materno Infantil de Badajoz, Badajoz, Spain
🇪🇸Hospital de Cruces-Baracaldo, Baracaldo, Spain
🇪🇸Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain
Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration
Completed
- Conditions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 100
- Registration Number
- NCT01195857
Assessment of Patient Use of a New Device: RebiSmart
Completed
- Conditions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 63
- Registration Number
- NCT01195870
© Copyright 2024. All Rights Reserved by MedPath